西洛他唑治疗脑出血：靶向硬脑膜淋巴系统
该研究在胶原酶诱导的脑出血小鼠模型中，评估口服临床等效剂量西洛他唑对硬脑膜淋巴功能及脑出血预后的影响。结果显示，西洛他唑可促进硬脑膜淋巴重塑与引流，促进血肿清除和神经功能恢复，且未加重初始出血或诱发血肿扩大。研究为正在进行的一项II期随机试验提供了机制与剂量依据。
要点
- 西洛他唑在脑出血后3小时或3天启用均能促进硬脑膜淋巴功能，改善长期神经功能。
- 西洛他唑治疗未加重初始出血，也未诱发血肿扩大。
- 该研究为II期随机试验NCT06504576提供了机制与剂量依据。
核心结论
- 口服西洛他唑通过促进硬脑膜淋巴重塑与引流，促进脑出血后血肿清除和神经功能恢复。
- 西洛他唑治疗未加重实验性脑出血的初始出血，也未诱发血肿扩大。
研究设计与样本
- 研究类型为动物实验，采用胶原酶注射诱导脑出血小鼠模型模拟微血管破裂。
- 西洛他唑以临床等效剂量口服给予脑出血小鼠，设置不同给药时间点和不同给药时长。
- 在健康小鼠体内及离体脑膜中检测西洛他唑的促淋巴管生成作用。
- 采用流式细胞术、免疫荧光、活体成像及荧光示踪剂引流组织学分析评估淋巴功能。
- 同时评估了短期和长期的组织病理学与行为学结局。
主要发现
- 脑出血后3小时或3天启动口服西洛他唑治疗，可增强硬脑膜淋巴覆盖和功能。
- 西洛他唑治疗可减少血肿体积、神经元损伤、突触丢失及长期神经功能缺损。
- 在健康小鼠中，西洛他唑增加离体脑膜中CD31+PDPN+淋巴内皮细胞数量。
- 西洛他唑诱导硬脑膜淋巴管增生，并增强健康小鼠的淋巴引流功能。
- 西洛他唑预处理和延迟治疗均未增加血肿体积，反而改善了脑出血结局。
关键数值与推荐
- 西洛他唑以临床等效剂量口服给药。
- 给药起始时间点为脑出血后3小时或3天。
临床怎么用
- 研究支持西洛他唑作为脑出血后促进血肿清除和神经功能恢复的潜在治疗选择。
- 研究结果为正在进行的一项II期随机试验提供了机制和剂量依据。
局限性
- 该研究为动物实验，其结果尚需临床研究进一步验证。
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
原文
Stroke, Volume 57, Issue 10, Page 3091-3105, October 1, 2026. BACKGROUND:The meningeal lymphatic system contributes to hematoma resolution and neurological recovery after intracerebral hemorrhage (ICH). We previously demonstrated that intraperitoneal cilostazol administration promotes dural lymphatic growth and enhances clearance of intracerebrally injected red blood cells; however, the antiplatelet effects of cilostazol raise safety concerns in ICH, potentially limiting clinical translation. Here, we evaluated whether oral cilostazol at clinical-equivalent doses in mice enhances dural lymphatic function and improves outcomes after ICH.METHODS:ICH was induced by collagenase injection to model microvascular rupture. Cilostazol was orally administered to ICH mice at clinically equivalent doses, given at different time points and for varying durations. Prolymphangiogenic effects of cilostazol were examined in healthy in vivo and ex vivo meninges. Flow cytometry and immunofluorescence were performed to assess lymphatic endothelial cell proliferation and dural lymphatic remodeling. Lymphatic function was evaluated by in vivo live imaging and histological analysis of fluorescent tracer drainage. Short- and long-term histopathologic and behavioral outcomes were also evaluated.RESULTS:Oral cilostazol treatment initiated either 3 hours or 3 days after ICH enhanced dural lymphatic coverage and function, accompanied by reduced hematoma volume, neuronal injury, synapse loss, and long-term neurological deficits. Cilostazol increased CD31+PDPN+lymphatic endothelial cells in ex vivo meninges, induced dural lymphatic hyperplasia, and enhanced lymphatic drainage in healthy mice. Both pretreatment and delayed treatment of cilostazol did not increase hematoma volume but rather improved ICH outcomes.CONCLUSIONS:By promoting dural lymphatic remodeling and drainage, cilostazol facilitates hematoma resolution and neurological recovery after ICH. Cilostazol treatment does not exacerbate initial bleeding or provoke hematoma expansion in the experimental ICH. These findings support clinical translation and provide mechanistic and dosing rationale for an ongoing phase II randomized trial (URL:https://www.clinicaltrials.gov; Unique identifier: NCT06504576).
引用
- Stroke：Cilostazol Treatment for Intracerebral Hemorrhage: Targeting Dural Lymphatics
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。